Short Interest in Alterity Therapeutics Limited (NASDAQ:ATHE) Declines By 22.4%

Alterity Therapeutics Limited (NASDAQ:ATHE) was the recipient of a large drop in short interest during the month of September. As of September 30th, there was short interest totalling 9,700 shares, a drop of 22.4% from the September 15th total of 12,500 shares. Based on an average daily trading volume, of 33,100 shares, the short-interest ratio is currently 0.3 days. Approximately 0.1% of the company’s shares are short sold.

Alterity Therapeutics Stock Performance

ATHE opened at $1.29 on Friday. Alterity Therapeutics has a 12 month low of $1.01 and a 12 month high of $5.41. The business has a 50-day moving average of $1.32 and a two-hundred day moving average of $1.73.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease.